What is Medigene?
Medigene is a publicly listed biotechnology firm based in Martinsried, Germany, dedicated to pioneering innovative immunotherapies for cancer treatment. The company's core scientific focus lies in developing advanced therapeutic modalities such as T cell receptor-modified T cells (TCR‑Ts) and dendritic cell (DC) vaccines. These cutting-edge treatments are designed to address high unmet medical needs in oncology, with initial product candidates currently undergoing clinical development. Medigene's strategic approach aims to leverage its deep scientific expertise to create next-generation cancer therapies.
How much funding has Medigene raised?
Medigene has raised a total of $117.7M across 1 funding round:
Stock Offering
$117.7M
Stock Issuance/Offering (2000): $117.7M, investors not publicly disclosed
What's next for Medigene?
The recent major strategic investment in Medigene signals a pivotal moment for the company's growth and development. This capital infusion is expected to accelerate the advancement of its promising immunotherapies through clinical trials and towards potential commercialization. Medigene's focus on TCR-Ts and DC vaccines places it at the forefront of personalized cancer treatment innovation. Future strategic initiatives will likely involve further research and development, potential partnerships, and navigating the complex regulatory pathways to bring these life-saving therapies to patients worldwide.
See full Medigene company page
